NeuroSense Therapeutics (NRSN) Competitors

NeuroSense Therapeutics logo
$1.16 -0.02 (-1.28%)
Closing price 02/14/2025 03:59 PM Eastern
Extended Trading
$1.18 +0.03 (+2.60%)
As of 02/14/2025 06:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NRSN vs. IPSC, ONCY, BLUE, PRLD, IOBT, HOWL, IMRX, OPTN, KRON, and ACHL

Should you be buying NeuroSense Therapeutics stock or one of its competitors? The main competitors of NeuroSense Therapeutics include Century Therapeutics (IPSC), Oncolytics Biotech (ONCY), bluebird bio (BLUE), Prelude Therapeutics (PRLD), IO Biotech (IOBT), Werewolf Therapeutics (HOWL), Immuneering (IMRX), OptiNose (OPTN), Kronos Bio (KRON), and Achilles Therapeutics (ACHL). These companies are all part of the "pharmaceutical products" industry.

NeuroSense Therapeutics vs.

NeuroSense Therapeutics (NASDAQ:NRSN) and Century Therapeutics (NASDAQ:IPSC) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, community ranking, analyst recommendations and profitability.

NeuroSense Therapeutics has higher earnings, but lower revenue than Century Therapeutics. NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than Century Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NeuroSense TherapeuticsN/AN/A-$11.28M-$0.64-1.80
Century Therapeutics$2.68M24.54-$136.67M-$1.85-0.42

Century Therapeutics received 35 more outperform votes than NeuroSense Therapeutics when rated by MarketBeat users. Likewise, 67.27% of users gave Century Therapeutics an outperform vote while only 66.67% of users gave NeuroSense Therapeutics an outperform vote.

CompanyUnderperformOutperform
NeuroSense TherapeuticsOutperform Votes
2
66.67%
Underperform Votes
1
33.33%
Century TherapeuticsOutperform Votes
37
67.27%
Underperform Votes
18
32.73%

NeuroSense Therapeutics has a beta of 1.27, meaning that its share price is 27% more volatile than the S&P 500. Comparatively, Century Therapeutics has a beta of 1.73, meaning that its share price is 73% more volatile than the S&P 500.

In the previous week, Century Therapeutics had 8 more articles in the media than NeuroSense Therapeutics. MarketBeat recorded 9 mentions for Century Therapeutics and 1 mentions for NeuroSense Therapeutics. Century Therapeutics' average media sentiment score of 1.08 beat NeuroSense Therapeutics' score of 1.00 indicating that Century Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
NeuroSense Therapeutics Positive
Century Therapeutics Positive

Century Therapeutics has a consensus target price of $10.00, indicating a potential upside of 1,191.16%. Given Century Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Century Therapeutics is more favorable than NeuroSense Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NeuroSense Therapeutics
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00
Century Therapeutics
0 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
3.00

NeuroSense Therapeutics has a net margin of 0.00% compared to Century Therapeutics' net margin of -4,837.73%. NeuroSense Therapeutics' return on equity of 0.00% beat Century Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
NeuroSense TherapeuticsN/A N/A -590.79%
Century Therapeutics -4,837.73%-61.66%-31.78%

1.0% of NeuroSense Therapeutics shares are held by institutional investors. Comparatively, 50.2% of Century Therapeutics shares are held by institutional investors. 27.4% of NeuroSense Therapeutics shares are held by company insiders. Comparatively, 6.8% of Century Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Century Therapeutics beats NeuroSense Therapeutics on 12 of the 17 factors compared between the two stocks.

Get NeuroSense Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NRSN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NRSN vs. The Competition

MetricNeuroSense TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$15.78M$6.84B$5.76B$9.22B
Dividend YieldN/A2.90%5.27%4.00%
P/E Ratio-1.809.7126.2219.45
Price / SalesN/A290.45456.5777.34
Price / CashN/A75.4646.0638.90
Price / Book-8.255.537.355.05
Net Income-$11.28M$123.46M$3.19B$222.81M
7 Day Performance2.21%1.37%1.69%1.29%
1 Month Performance5.96%2.09%4.13%1.52%
1 Year Performance-15.69%1.28%22.24%16.53%

NeuroSense Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NRSN
NeuroSense Therapeutics
1.1454 of 5 stars
$1.16
-1.3%
N/A-15.7%$15.78MN/A-1.8010Short Interest ↓
IPSC
Century Therapeutics
2.3786 of 5 stars
$0.72
-0.5%
$10.00
+1,285.2%
-83.5%$61.38M$2.23M-0.39170Analyst Revision
News Coverage
Positive News
ONCY
Oncolytics Biotech
1.8143 of 5 stars
$0.77
-1.5%
$4.00
+422.8%
-33.9%$61.22MN/A-2.8330Short Interest ↑
BLUE
bluebird bio
1.7237 of 5 stars
$6.29
flat
$49.14
+681.3%
-64.4%$61.14M$29.50M-0.17520
PRLD
Prelude Therapeutics
2.2233 of 5 stars
$1.09
+7.9%
$4.00
+267.0%
-79.0%$59.98MN/A-0.61120Upcoming Earnings
Gap Up
High Trading Volume
IOBT
IO Biotech
3.9239 of 5 stars
$0.91
-5.3%
$9.33
+931.2%
-41.4%$59.63MN/A-0.6630Short Interest ↓
Gap Down
HOWL
Werewolf Therapeutics
2.3294 of 5 stars
$1.33
-2.2%
$9.33
+601.8%
-78.4%$59.27M$19.94M-0.8740Positive News
IMRX
Immuneering
3.374 of 5 stars
$1.86
-2.1%
$12.20
+555.9%
-71.8%$57.75M$320,000.00-0.9460Short Interest ↓
Gap Up
OPTN
OptiNose
4.1146 of 5 stars
$5.70
-1.9%
$16.67
+192.4%
-70.7%$57.34M$75.67M-1.36190Short Interest ↑
News Coverage
KRON
Kronos Bio
3.6748 of 5 stars
$0.95
-2.3%
$1.63
+71.5%
+0.0%$57.17M$6.29M-0.66100News Coverage
ACHL
Achilles Therapeutics
3.652 of 5 stars
$1.39
+0.7%
$4.00
+187.8%
+30.2%$57.13MN/A-0.84250

Related Companies and Tools


This page (NASDAQ:NRSN) was last updated on 2/17/2025 by MarketBeat.com Staff
From Our Partners